Follmann D - Search Results

1

Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration.

Follmann D, O'Brien MP, Fintzi J, Fay MP, Montefiori D, Mateja A, Herman GA, Hooper AT, Turner KC, Chan KC, Forleo-Neto E, Isa F, Baden LR, El Sahly HM, Janes H, Doria-Rose N, Miller J, Zhou H, Dang W, Benkeser D, Fong Y, Gilbert PB, Marovich M, Cohen MS. Follmann D, et al. Nat Commun. 2023 Jun 17;14(1):3605. doi: 10.1038/s41467-023-39292-w. Nat Commun. 2023. PMID: 37330602 Free PMC article. Clinical Trial.

2

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial.

Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M, Heyward WL, Jobes DV, Popovic V, Self SG, Sinangil F, Burke D, Berman PW. Gilbert PB, et al. Among authors: follmann d. J Infect Dis. 2005 Mar 1;191(5):666-77. doi: 10.1086/428405. Epub 2005 Jan 27. J Infect Dis. 2005. PMID: 15688279 Clinical Trial.

3

Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop.

Follmann D, Duerr A, Tabet S, Gilbert P, Moodie Z, Fast P, Cardinali M, Self S. Follmann D, et al. J Acquir Immune Defic Syndr. 2007 Jan 1;44(1):49-60. doi: 10.1097/01.qai.0000247227.22504.ce. J Acquir Immune Defic Syndr. 2007. PMID: 17075387 Free PMC article.

4

Accounting for variability in sample size estimation with applications to nonadherence and estimation of variance and effect size.

Fay MP, Halloran ME, Follmann DA. Fay MP, et al. Biometrics. 2007 Jun;63(2):465-74. doi: 10.1111/j.1541-0420.2006.00703.x. Biometrics. 2007. PMID: 17688499

5

ASSESSING SURROGATE ENDPOINTS IN VACCINE TRIALS WITH CASE-COHORT SAMPLING AND THE COX MODEL.

Qin L, Gilbert PB, Follmann D, Li D. Qin L, et al. Among authors: follmann d. Ann Appl Stat. 2008 Mar;2(1):386-407. doi: 10.1214/07-AOAS132. Ann Appl Stat. 2008. PMID: 19079758 Free PMC article.

6

Chop-lump tests for vaccine trials.

Follmann D, Fay MP, Proschan M. Follmann D, et al. Biometrics. 2009 Sep;65(3):885-93. doi: 10.1111/j.1541-0420.2008.01131.x. Epub 2009 Feb 5. Biometrics. 2009. PMID: 19210727

7

Exact inference for complex clustered data using within-cluster resampling.

Follmann D, Fay M. Follmann D, et al. J Biopharm Stat. 2010 Jul;20(4):850-69. doi: 10.1080/10543401003618884. J Biopharm Stat. 2010. PMID: 20496210 Free PMC article.

8

A valid formulation of the analysis of noninferiority trials under random effects meta-analysis.

Brittain EH, Fay MP, Follmann DA. Brittain EH, et al. Biostatistics. 2012 Sep;13(4):637-49. doi: 10.1093/biostatistics/kxs006. Epub 2012 Mar 30. Biostatistics. 2012. PMID: 22467938 Free PMC article.

9

Bounds on the effect of vaccine induced immune response on outcome.

Follmann D, Fay M. Follmann D, et al. Int J Biostat. 2012 Jan 6;8(2):/j/ijb.2012.8.issue-2/1557-4679.1348/1557-4679.1348.xml. doi: 10.2202/1557-4679.1348. Int J Biostat. 2012. PMID: 22499733 Free article.

10

Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challenge.

Fay MP, Follmann DA, Lynn F, Schiffer JM, Stark GV, Kohberger R, Quinn CP, Nuzum EO. Fay MP, et al. Sci Transl Med. 2012 Sep 12;4(151):151ra126. doi: 10.1126/scitranslmed.3004073. Sci Transl Med. 2012. PMID: 22972844 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

270 results

Search Page

Filters